România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

medac gesellscaft fur klinische spezialprÄparate - germania - bleomycinum sulfas - pulb. pt. sol. inj. - 15000ui - antibiotice citotoxice si substante inrudite alte antibiotice citotoxice

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

naprod life sciences private limited - bleomycinum - pulbere pentru soluţie injectabilă - 15 ui

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

neon laboratories limited - bleomycinum - liofilizat pentru solutie injectabila - 15 ui

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sanofi aventis deutschland gmbh - germania - bleomycinum sulfas - pulb. pt. sol. inj. - 15mg - antibiotice citotoxice si substante inrudite alte antibiotice citotoxice

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

naprod life sciences pvt. ltd. - liofilizat pentru solutie injectabila - 15 ui

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare limited - marea britanie - bleomycinum sulfas - pulb. pt. sol. inj./perf. - 15000ui - antibiotice citotoxice si substante inrudite alte antibiotice citotoxice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare polska sp. z.o.o. - polonia - bleomycinum sulfas - pulb. pt. sol. inj./perf. - 15000ui - antibiotice citotoxice si substante inrudite alte antibiotice citotoxice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

kocak farmailac ve kimya sanayi a.s. - turcia - bleomycinum sulfas - pulb. pt. sol. inj. - 15mg - antibiotice citotoxice si substante inrudite alte antibiotice citotoxice

Uniunea Europeană - română - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicină clorhidrat - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agenți antineoplazici - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

polfa sa, tarchomin - neomycinum - spray cutanat, suspensie - 11,72 mg/g